Novo Nordisk A/S (NVO · NYSE)
NVO · MARKET VIEW
Market view · as of Jun 8, 2026
Revenue (TTM)
$327.80B
+24.0% YoY
Gross margin
83.2%
EPS (latest q)
$6.63
vs $6.96 est · miss
52-wk position
19.0%
-44.6% vs 52w high · -6.2% 1mo
Price (last ~year)
Novo Nordisk is expanding its pharmaceutical focus beyond obesity treatments, recently reporting over three million prescriptions for its Wegovy oral tablet and positive phase 2 results for the experimental drug zenagamtide. The company reports an 83.2% gross margin and 24.0% year-over-year revenue growth, with TTM revenue reaching $327.80 billion. Shares closed at $42.96, marking a 14.5% gain over the last three months despite a 6.2% decline in the past month.
Valuation
- Market cap
- $190.31B
- P/E
- 10.08
- PEG
- 3.17
- P/B
- 6.03
- P/S
- 0.581
- EV/EBITDA
- 7.68
- Beta
- 0.349
- Analyst target
- $46.9
Quality & returns
- Gross margin
- 83.2%
- Operating margin
- 61.6%
- Profit margin
- 37.2%
- ROE
- 71.4%
- ROA
- 19.3%
Price movement
- Last
- $42.96
- 1-month
- -6.2%
- 3-month
- +14.5%
- RSI (14)
- 42
- vs SMA200
- -9.4%
- 52-wk position
- 19.0% -44.6% vs high
Quarterly trajectory
Revenue by quarter (oldest → newest)
| Quarter | Revenue | Op income | Net income | EBITDA |
|---|---|---|---|---|
| 2026-03-31 | $96.82B | $59.62B | $48.56B | $69.21B |
| 2025-12-31 | $79.14B | $31.74B | $26.89B | $37.30B |
| 2025-09-30 | $74.98B | $23.68B | $20.01B | $31.44B |
| 2025-06-30 | $76.86B | $33.45B | $26.50B | $43.60B |
Recent news
- Somewhat-Bullish Novo Nordisk CEO looks beyond weight loss to longevity and aesthetics · 2026-06-07
- Bullish Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk unveils new data at ADA 2026 · 2026-06-07
- Neutral Novo Nordisk’s zenagamtide shows 14.6% weight-loss in mid-stage diabetes study · 2026-06-06
- Bullish Novo Nordisk's investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes--presented at ADA 2026 · 2026-06-05
- Neutral Lilly and Novo face off at ADA 2026 as others seek to compete in obesity · 2026-06-05
- Bullish Novo Nordisk launches Wegovy pill in UAE, its first global market · 2026-06-03
Sources this view read
- fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
- filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
- earnings Reported earnings history (Alpha Vantage EARNINGS)
- prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)